Aliases & Classifications for Sensorineural Hearing Loss

MalaCards integrated aliases for Sensorineural Hearing Loss:

Name: Sensorineural Hearing Loss 12 72 28 14 69
Sensory Hearing Loss 12 51 69
Hearing Loss, High-Frequency 41 69
Hearing Loss, Central 41 69
Perceptive Hearing Loss or Deafness 12
High Frequency Hearing Loss 12
High-Frequency Hearing Loss 12
Hearing Loss High-Frequency 51
Hearing Loss, Sensorineural 41
Hearing Loss Sensorineural 51
High Frequency Deafness 12
Perceptive Hearing Loss 12
Sensorineural Deafness 12
Deafness Sensorineural 51
Central Hearing Loss 12
Perceptive Deafness 12

Classifications:



Summaries for Sensorineural Hearing Loss

MalaCards based summary : Sensorineural Hearing Loss, also known as sensory hearing loss, is related to deafness, x-linked 2 and deafness, autosomal recessive 1b, and has symptoms including tinnitus An important gene associated with Sensorineural Hearing Loss is GJB2 (Gap Junction Protein Beta 2), and among its related pathways/superpathways are G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins and Neural Crest Differentiation. The drugs Cisplatin and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are hearing/vestibular/ear and behavior/neurological

Wikipedia : 72 Sensorineural hearing loss (SNHL) is a type of hearing loss, or deafness, in which the root cause lies... more...

Related Diseases for Sensorineural Hearing Loss

Diseases related to Sensorineural Hearing Loss via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 660)
# Related Disease Score Top Affiliating Genes
1 deafness, x-linked 2 33.6 GJB2 GJB6
2 deafness, autosomal recessive 1b 32.7 GJB2 GJB6
3 deafness, autosomal dominant 22 32.7 COCH MYH9 MYO6 MYO7A
4 pendred syndrome 32.7 GJB2 MITF SLC26A4
5 deafness, autosomal recessive 9 32.6 GJB2 OTOF
6 auditory neuropathy, autosomal dominant, 1 32.6 GJB2 OTOF
7 deafness, autosomal dominant 36 32.5 GJB2 SLC26A4 TMC1
8 deafness, autosomal recessive 7 32.5 GJB2 TMC1
9 deafness, autosomal recessive 23 32.5 GJB2 MYO7A SLC26A4
10 deafness, autosomal recessive 63 32.4 GJB2 MYO7A TMC1
11 deafness, autosomal dominant 48 32.3 MYH9 MYO6 MYO7A
12 deafness, autosomal recessive 37 32.3 MYH9 MYO6 MYO7A
13 deafness, autosomal recessive 6 32.3 GJB2 MYO7A USH2A
14 deafness, autosomal dominant 11 32.2 MYO6 MYO7A
15 deafness, autosomal recessive 2 32.2 GJB2 MYO6 MYO7A OTOF
16 knuckle pads, leukonychia, and sensorineural deafness 32.1 GJB2 GJB6
17 usher syndrome 32.0 CEP78 GJB2 MYO7A USH2A
18 deafness, autosomal recessive 3 32.0 GJB2 MYO7A
19 deafness, autosomal recessive 28 31.9 GJB2 GJB3
20 deafness, autosomal recessive 1a 31.9 GJB2 GJB3 GJB6
21 deafness, autosomal dominant 2a 31.6 COCH GJB2 GJB6 KCNQ4 WFS1
22 usher syndrome, type iiia 31.6 CEP78 MYO7A USH2A
23 deafness, autosomal dominant 6 31.5 COCH GJB2 MYO7A OTOF SLC26A4 WFS1
24 deafness, autosomal recessive 16 31.5 COCH GJB2 GJB6 MYO7A OTOF SLC26A4
25 congenital cytomegalovirus 31.4 GJB2 GJB6
26 deafness, autosomal dominant 24 31.2 GJB2 GJB6
27 deafness, autosomal recessive 12 31.2 GJB2 GJB3 GJB6 MYO7A SLC26A4 WFS1
28 deafness, autosomal recessive 59 31.2 GJB2 OTOF
29 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 31.1 GJB2 GJB3 MITF
30 deafness, autosomal recessive 26 31.1 GJB2 OTOF SLC26A4
31 deafness, autosomal dominant 13 31.0 COCH GJB2 MYO7A OTOF SLC26A4 USH2A
32 deafness, autosomal recessive 85 30.9 MYO7A OTOF SLC26A4
33 deafness, autosomal recessive 83 30.9 MYO7A OTOF SLC26A4
34 autosomal recessive nonsyndromic deafness 30.8 GJB2 OTOF SLC26A4 TMC1
35 deafness, autosomal dominant 17 30.8 MYH9 MYO6 MYO7A
36 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 30.6 COCH GJB2 GJB3 GJB6 MYO7A OTOF
37 hypotrichosis-deafness syndrome 30.5 GJB2 GJB3
38 deafness, autosomal recessive 93 30.5 GJB2 GJB3
39 dfnb1 30.3 GJB2 GJB6 MYO7A OTOF
40 autosomal recessive nonsyndromic deafness 3 30.3 GJB2 MYH9 MYO6 MYO7A OTOF SLC26A4
41 deafness, autosomal recessive 30 30.2 GJB2 MYH9 MYO6 MYO7A SLC26A4 TMC1
42 autosomal dominant non-syndromic sensorineural deafness type dfna 30.1 COCH GJB2 GJB3 GJB6 KCNQ4 MYH9
43 knuckle pads 30.1 GJB2 GJB3 GJB6
44 kid syndrome 29.7 GJB2 GJB3 GJB6
45 clouston syndrome 29.6 GJB2 GJB3 GJB6
46 non-syndromic genetic deafness 29.2 COCH GJB2 GJB6 KCNQ4 MYO6 OTOF
47 retinitis pigmentosa 29.1 CEP78 GJB2 GJB6 MYO7A SLC26A4 USH2A
48 autosomal dominant nonsyndromic deafness 29.0 COCH GJB2 KCNQ4 MYH9 MYO6 MYO7A
49 skin disease 28.9 GJB2 GJB3 GJB6
50 autosomal recessive non-syndromic sensorineural deafness type dfnb 28.7 GJB2 GJB3 GJB6 MYH9 MYO6 MYO7A

Comorbidity relations with Sensorineural Hearing Loss via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Sensorineural Hearing Loss:



Diseases related to Sensorineural Hearing Loss

Symptoms & Phenotypes for Sensorineural Hearing Loss

UMLS symptoms related to Sensorineural Hearing Loss:


tinnitus

MGI Mouse Phenotypes related to Sensorineural Hearing Loss:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 10.13 MYH9 ATP6V1B1 COCH MYO6 COL2A1 MYO7A
2 behavior/neurological MP:0005386 10.06 WFS1 ATP6V1B1 MYO6 COL2A1 MYO7A DLX5
3 nervous system MP:0003631 10 MYH9 ATP6V1B1 MYO6 COL2A1 MYO7A DLX5
4 no phenotypic analysis MP:0003012 9.56 MYH9 MYO7A GJB2 OTOF GJB3 SERPINB6
5 vision/eye MP:0005391 9.23 MITF MYH9 MYO6 COL2A1 COL4A5 MYO7A

Drugs & Therapeutics for Sensorineural Hearing Loss

Drugs for Sensorineural Hearing Loss (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 1,Phase 2 15663-27-1 2767 441203 84093
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
5 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
6 glucocorticoids Phase 4,Phase 2,Phase 3
7 Hormone Antagonists Phase 4,Phase 2,Phase 3
8 Hormones Phase 4,Phase 2,Phase 3
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
11 Antiemetics Phase 4,Phase 3,Phase 2
12 Autonomic Agents Phase 4,Phase 3,Phase 2
13 BB 1101 Phase 4,Phase 3,Phase 2
14 Dexamethasone 21-phosphate Phase 4,Phase 2
15 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
16 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
17 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
18
protease inhibitors Phase 4,Phase 3,Phase 2
19
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
20
Ganciclovir Approved, Investigational Phase 3,Phase 2 82410-32-0 3454
21
Valganciclovir Approved, Investigational Phase 3,Phase 2 175865-60-8 64147
22
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
23
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
25
Acetylcysteine Approved, Investigational Phase 2, Phase 3,Phase 1 616-91-1 12035
26
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
27
Povidone Approved Phase 3 9003-39-8
28
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
29
Iron Approved Phase 2, Phase 3 7439-89-6 23925
30
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
31
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
32
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 3,Phase 2,Phase 1
37 Ganciclovir triphosphate Phase 3,Phase 2
38 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
39 Acyclovir Phase 2, Phase 3
40 Analgesics Phase 3,Phase 1,Phase 2
41 Anesthetics Phase 3,Phase 1,Phase 2
42 Anti-Arrhythmia Agents Phase 3
43 Anticonvulsants Phase 3
44 calcium channel blockers Phase 3
45 Calcium, Dietary Phase 3
46 Central Nervous System Depressants Phase 3
47 Tocolytic Agents Phase 3
48 Methylprednisolone acetate Phase 3
49 Methylprednisolone Hemisuccinate Phase 3
50 Neuroprotective Agents Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 115)

# Name Status NCT ID Phase Drugs
1 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
2 Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study Completed NCT01054378 Phase 4
3 Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss Unknown status NCT00416143 Phase 2, Phase 3 prednisone - oral corticosteroid 1mg/kg/D for 1 week
4 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
5 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
6 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
7 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
8 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
9 Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss Completed NCT00335920 Phase 3 Dexamethasone-dihydrogenphosphate (4mg/ml)
10 Evaluation of a Binaural Spatialization Method for Hearing Aids Completed NCT02693704 Phase 2, Phase 3
11 Sudden Deafness Treatment Trial Completed NCT00097448 Phase 3 prednisone;methylprednisolone sodium succinate
12 Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Recruiting NCT03374514 Phase 3 Dexamethasone;Sterile isotonic saline solution
13 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Recruiting NCT01376778 Phase 3 CMV hyperimmune globulin
14 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment Active, not recruiting NCT02809118 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
15 Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL Not yet recruiting NCT03331627 Phase 3 STR001-IT and STR001-ER
16 Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance Not yet recruiting NCT02606266 Phase 2, Phase 3 Valganciclovir
17 Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants Not yet recruiting NCT03107871 Phase 3 Valganciclovir;Simple Syrup
18 Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Not yet recruiting NCT02882477 Phase 2, Phase 3 Deferiprone;Acetylcysteine;Sitagliptin and Metformin
19 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Terminated NCT01655212 Phase 3 Valganciclovir
20 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
21 Effectiveness of P02 Digital Hearing Aids Unknown status NCT01902914 Phase 1, Phase 2
22 Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity Unknown status NCT01108601 Phase 1, Phase 2 Ringer's Lactate (0.03% Ciprofloxacin)
23 Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss Completed NCT00802425 Phase 2 AM-111;placebo
24 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
25 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
26 Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus Completed NCT00860808 Phase 2 AM-101
27 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease Completed NCT01133860 Phase 2 eltrombopag
28 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
29 High Dose Oral Steroids in Sudden Sensorineural Hearing Loss Recruiting NCT03255473 Phase 2 Dexamethasone;Prednisone
30 Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Recruiting NCT01621256 Phase 1, Phase 2 Ancrod;Saline solution
31 Effectiveness of Therapy Via Telemedicine Following Cochlear Implants Recruiting NCT02497690 Phase 2
32 SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity Enrolling by invitation NCT02819856 Phase 1, Phase 2 Placebo;SPI-1005 Ebselen 200mg Capsule x1;SPI-1005 Ebselen 200mg Capsule x2;SPI-1005 Ebselen 200mg Capsule x3
33 SPI-1005 for the Treatment of Patients With Meniere's Disease Enrolling by invitation NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
34 Asymptomatic Congenital CMV Treatment Not yet recruiting NCT03301415 Phase 2 Valganciclovir
35 Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Suspended NCT02616172 Phase 1, Phase 2
36 Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Suspended NCT02038972 Phase 1, Phase 2
37 Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss Terminated NCT02414152 Phase 1, Phase 2 anakinra
38 A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss Completed NCT01518920 Phase 1 PF-04958242;PF-04958242;Placebo
39 Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding Completed NCT00582946 Phase 1
40 Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Completed NCT02259595 Phase 1 HPN-07;NAC;Placebo
41 Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Unknown status NCT02093806
42 Fludrocortisone for Sudden Hearing Loss Unknown status NCT01186185 Fludrocortisone
43 Middle-Ear Implant With MET V Transducer (Aka MET V System) Unknown status NCT01529333
44 Cochlear Implant and Vestibular Function. Unknown status NCT02584361
45 Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old Unknown status NCT00140699
46 Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Completed NCT00787189
47 Central Auditory Processing and the Use of Hearing Aids Completed NCT01897181
48 Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study Completed NCT00589511
49 Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System Completed NCT00678899
50 Radiological Classification of the Facial Nerve Completed NCT02925208

Search NIH Clinical Center for Sensorineural Hearing Loss

Cochrane evidence based reviews: hearing loss, central

Genetic Tests for Sensorineural Hearing Loss

Genetic tests related to Sensorineural Hearing Loss:

# Genetic test Affiliating Genes
1 Sensorineural Hearing Loss 28

Anatomical Context for Sensorineural Hearing Loss

MalaCards organs/tissues related to Sensorineural Hearing Loss:

38
Bone, Testes, Brain, Bone Marrow, Endothelial, Neutrophil, Heart

Publications for Sensorineural Hearing Loss

Articles related to Sensorineural Hearing Loss:

(show top 50) (show all 1046)
# Title Authors Year
1
Association of Sudden Sensorineural Hearing Loss With Risk of Cardiocerebrovascular Disease: A Study Using Data From the Korea National Health Insurance Service. ( 29270613 )
2018
2
Resolution of unilateral sensorineural hearing loss in a pediatric patient with a severe phenotype of Muckle-Wells syndrome treated with Anakinra: a case report and review of the literature. ( 29382382 )
2018
3
Mobile phone usage does not affect sudden sensorineural hearing loss. ( 29179790 )
2018
4
Comparison of 2 and 4 Intratympanic Steroid Injections in the Treatment of Idiopathic Sudden Sensorineural Hearing Loss. ( 29411622 )
2018
5
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
6
Comparison between Bilateral and Unilateral Sudden Sensorineural Hearing Loss. ( 29363646 )
2018
7
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2. ( 29416648 )
2018
8
The role of explorative tympanotomy in patients with sudden sensorineural hearing loss with and without perilymphatic fistula. ( 29055686 )
2018
9
Bony cochlear nerve canal stenosis in pediatric unilateral sensorineural hearing loss. ( 29447896 )
2018
10
Does the addition of hyperbaric oxygen therapy to conventional treatment modalities influence the outcome of soldiers with idiopathic sudden sensorineural hearing loss? ( 29431146 )
2018
11
Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media. ( 29331307 )
2018
12
Inpatient treatment of patients with idiopathic sudden sensorineural hearing loss: a population-based healthcare research study. ( 29330597 )
2018
13
Which Patients With Asymmetric Sensorineural Hearing Loss Should Undergo Imaging? ( 29392735 )
2018
14
Association of Metabolic Syndrome With Sudden Sensorineural Hearing Loss. ( 29450496 )
2018
15
Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection. ( 29441223 )
2018
16
Predicting the hearing outcome in sudden sensorineural hearing loss via machine learning models. ( 29356346 )
2018
17
Can A Sudden Sensorineural Hearing Loss Occur Due to Miliary Tuberculosis? ( 29036759 )
2018
18
Reply to the Letter: "Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection". ( 29443330 )
2018
19
Total serum bilirubin levels and sensorineural hearing loss in the US adolescents: NHANES 2007-2010. ( 29447812 )
2018
20
International consensus (ICON) on treatment of sudden sensorineural hearing loss. ( 29396226 )
2018
21
Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. ( 29149379 )
2018
22
Unilateral Sensorineural Hearing Loss Presenting With Bilateral Temporal Bone Lesions. ( 29342040 )
2018
23
Mobile Hearing Testing Applications and the Diagnosis of Sudden Sensorineural Hearing Loss: A Cautionary Tale. ( 29227445 )
2018
24
Sensorineural hearing loss in patients with chronic suppurative otitis media: Is there a significant correlation? ( 28465813 )
2017
25
Early cortical metabolic rearrangement related to clinical data in idiopathic sudden sensorineural hearing loss. ( 28460253 )
2017
26
Prognosticating hearing outcome in patients with idiopathic sudden sensorineural hearing loss by means of otoacoustic emissions and auditory brainstem response. ( 29236273 )
2017
27
Glutathione peroxidase 3 gene polymorphisms and the risk of sudden sensorineural hearing loss. ( 28738977 )
2017
28
Anisomorphic Cortical Reorganization in Asymmetric Sensorineural Hearing Loss. ( 28515283 )
2017
29
Necessity of admission to improve the hearing-recovery rate in idiopathic sudden sensorineural hearing loss. ( 29130359 )
2017
30
Long-Term Progression of Sensorineural Hearing Loss and Tinnitus after Combined Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma: A Case Report. ( 28878660 )
2017
31
Possible mechanisms for sensorineural hearing loss and deafness in patients with propionic acidemia. ( 28193246 )
2017
32
Sealing of the round and oval window niches with triamcinolone-soaked fascia as salvage surgical therapy in sudden sensorineural hearing loss. ( 28415914 )
2017
33
Whole-exome sequencing to identify the cause of congenital sensorineural hearing loss in carriers of a heterozygous GJB2 mutation. ( 28821934 )
2017
34
Whole exome sequencing identifies TRIOBP pathogenic variants as a cause of post-lingual bilateral moderate-to-severe sensorineural hearing loss. ( 29197352 )
2017
35
Biochemical alteration in children with idiopathic nephrotic syndrome associated with an increased risk of sensorineural hearing loss; additional insights in cochlear renal relationship. ( 28483237 )
2017
36
Idiopathic sudden sensorineural hearing loss and mAcniA"re syndrome: The role of cerebral venous drainage. ( 28744995 )
2017
37
Anti-mumps IgM antibody positive rate with sudden sensorineural hearing loss using second-generation enzyme immunoassay: A retrospective, multi-institutional investigation in Hokkaido, Japan. ( 29224848 )
2017
38
Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up. ( 29094069 )
2017
39
Prognostic Factors for Recovery from Sudden Sensorineural Hearing Loss: A Retrospective Study. ( 28417102 )
2017
40
The Role of High Dose Intratympanic Dexamethasone as Salvage Therapy for Idiopathic Sudden Sensorineural Hearing Loss. ( 29165312 )
2017
41
A common variant in CLDN14 causes precipitous, prelingual sensorineural hearing loss in multiple families due to founder effect. ( 27838790 )
2017
42
Vibrant Soundbridge can improve the most comfortable listening level in sensorineural hearing loss: Our experience with 61 patients. ( 28834277 )
2017
43
Intratympanic steroid delivery by an indwelling catheter in refractory severe sudden sensorineural hearing loss. ( 28511890 )
2017
44
An update on drug design strategies to prevent acquired sensorineural hearing loss. ( 28838250 )
2017
45
COQ6 Mutations in Children With Steroid-Resistant Focal Segmental Glomerulosclerosis and Sensorineural Hearing Loss. ( 28117207 )
2017
46
Sudden sensorineural hearing loss in children and adolescents: Clinical characteristics and age-related prognosis. ( 28888426 )
2017
47
Effects of Various Extents of High-Frequency Hearing Loss on Speech Recognition and Gap Detection at Low Frequencies in Patients with Sensorineural Hearing Loss. ( 29445551 )
2017
48
Evaluation of Procalcitonin and hs-CRP Levels in Sudden Sensorineural Hearing Loss. ( 28639554 )
2017
49
A sustained increase of plasma fibrinogen in sudden sensorineural hearing loss predicts worse outcome independently. ( 28502595 )
2017
50
Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide. ( 28578424 )
2017

Variations for Sensorineural Hearing Loss

Copy number variations for Sensorineural Hearing Loss from CNVD:

7 (show all 13)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 115500 17 58121080 60118579 Deletion Sensorineural hearing loss
2 115503 17 58121080 60118579 Deletion APPBP2 sensorineural hearing loss
3 115507 17 58121080 60118579 Deletion BCAS3 sensorineural hearing loss
4 115511 17 58121080 60118579 Deletion BRIP1 sensorineural hearing loss
5 115515 17 58121080 60118579 Deletion CA4 sensorineural hearing loss
6 115519 17 58121080 60118579 Deletion INTS2 sensorineural hearing loss
7 115523 17 58121080 60118579 Deletion MED13 sensorineural hearing loss
8 115527 17 58121080 60118579 Deletion NACA2 sensorineural hearing loss
9 115531 17 58121080 60118579 Deletion PPM1D sensorineural hearing loss
10 115535 17 58121080 60118579 Deletion TBX2 sensorineural hearing loss
11 115539 17 58121080 60118579 Deletion TBX4 sensorineural hearing loss
12 115543 17 58121080 60118579 Deletion USP32 sensorineural hearing loss
13 115552 17 58172730 60315273 Deletion Sensorineural hearing loss

Expression for Sensorineural Hearing Loss

Search GEO for disease gene expression data for Sensorineural Hearing Loss.

Pathways for Sensorineural Hearing Loss

GO Terms for Sensorineural Hearing Loss

Cellular components related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.55 ATP6V1B1 GJB6 MYO7A SLC26A4 USH2A
2 basement membrane GO:0005604 9.54 COL2A1 COL4A5 USH2A
3 microvillus GO:0005902 9.5 ATP6V1B1 MYO6 MYO7A
4 myosin complex GO:0016459 9.43 MYH9 MYO6 MYO7A
5 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
6 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.71 COL2A1 MYO7A USH2A WFS1
2 ossification GO:0001503 9.63 ATP6V1B1 COL2A1 DLX5
3 cell communication GO:0007154 9.5 GJB2 GJB3 GJB6
4 regulation of pH GO:0006885 9.48 ATP6V1B1 SLC26A4
5 sensory perception of sound GO:0007605 9.47 ATP6V1B1 COCH COL2A1 GJB2 GJB6 KCNQ4
6 inner ear development GO:0048839 9.46 COL2A1 GJB2 GJB6 MYO7A
7 sensory perception of light stimulus GO:0050953 9.43 MYO7A USH2A
8 actin filament-based movement GO:0030048 9.43 MYH9 MYO6 MYO7A
9 inner ear receptor cell differentiation GO:0060113 9.37 MYO7A USH2A
10 inner ear morphogenesis GO:0042472 9.35 ATP6V1B1 COL2A1 DLX5 KCNQ4 MYO7A

Molecular functions related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 motor activity GO:0003774 9.5 MYH9 MYO6 MYO7A
2 microfilament motor activity GO:0000146 9.37 MYH9 MYO7A
3 gap junction channel activity GO:0005243 9.26 GJB2 GJB3
4 calmodulin binding GO:0005516 9.26 MYH9 MYO6 MYO7A WFS1
5 actin-dependent ATPase activity GO:0030898 9.16 MYH9 MYO7A
6 ADP binding GO:0043531 8.8 MYH9 MYO6 MYO7A

Sources for Sensorineural Hearing Loss

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....